Taking flibanserin with alcohol does not appear to add to adverse events, according to a recent alcohol-interaction study. Approved in the United States and Canada, flibanserin is an oral medication for the treatment of acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Women with HSDD have a persistent, distressing lack of or decrease […]
The International Society for Sexual Medicine (ISSM), along with the International Society for the Study of Women’s Sexual Health (ISSWSH) and nine other medical organizations, has endorsed the “Global Consensus Position Statement on the Use of Testosterone Therapy for Women.” The position statement provides guidelines for clinicians who consider prescribing testosterone therapy to female patients. […]
Earlier this month, the U.S. Food and Drug Administration (FDA) changed the safety labeling for Addyi (flibanserin), a medication used to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Women with this type of HSDD have little or no interest in sex, even though they have had a satisfying libido in the […]
Aromatase inhibitors (AIs) are associated with hypoactive sexual desire disorder (HSDD) and fecal incontinence in breast cancer survivors ten years after diagnosis, according to a recent Journal of Sexual Medicine study.
On June 4, an advisory panel to the U.S. Food and Drug Administration (FDA) voted 18-6 in favor of recommending the approval of flibanserin for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in the United States.
In this study, the researchers questioned whether levels of circulating androgens (including ADT-G) and 17b-hydroxysteroid dehydrogenase activity would correlate with sexual desire in women overall and at certain life stages.